Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...

Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...

Bristol Myers said about 5% to 7% of people with metastatic colorectal cancer have microsatellite instability-high or mismatch-repair-deficient tumors, adding that these patients are less likely to ...

In a regulatory filing on Friday night, Bristol Myers (BMY) disclosed that its CEO Christopher Boerner bought 2K shares of common stock on ...

The application was based on results from the three-arm Phase 3 CheckMate -8HW study.

Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid long-term pick despite short-term risks.

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

For the Bristol Myers Squibb (BMS) treasury function, innovation has long been fundamental. Still, after integrating with ...